Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia
RATIONALE: Studying samples of blood or tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in samples from patients with Down syndrome and acute megakaryoblastic leukemia.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Development of Novel Therapeutics for AMKL|
- Proliferation arrest [ Designated as safety issue: No ]
- Polyploidization [ Designated as safety issue: No ]
- Terminal differentiation [ Designated as safety issue: No ]
|Study Start Date:||July 2009|
|Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
- Determine whether megakaryocyte differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor can lead to proliferation arrest, polyploidization, and terminal differentiation of blasts in specimens from patients with Down syndrome and acute megakaryoblastic leukemia.
OUTLINE: Cryopreserved specimens are cultured and treated in vivo (in mice) and in vitro with megakaryocytic differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01139307
|Principal Investigator:||John Crispino, PhD||Robert H. Lurie Cancer Center|